Floatz logo

TECHNETIUM TC 99M SESTAMIBI

Renal Neoplasms

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Renal Neoplasms cohort.

Asset / SponsorPhaseRating
Vinorelbine
National Cancer Institute (NCI)
Phase 2B
Docetaxel
National Cancer Institute (NCI)
Phase 2B
Tariquidar
National Cancer Institute (NCI)
Phase 2CCC
Guadecitabine
National Cancer Institute (NCI)
Phase 2CCC

Same molecule, other indications

TECHNETIUM TC 99M SESTAMIBI is also rated in:

Cervix NeoplasmsDormant
B
Indicative ·
57 / 100
View asset →
Ovarian NeoplasmsDormant
CCC
Indicative ·
54 / 100
View asset →
Lung NeoplasmsDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →